Skip to main content

QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.

Press release date / time: Tuesday, February 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Wednesday, February 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.

Three options for joining the conference call

Register for call back connection


Click here:

Connect me


Service available 15 minutes before call start

Dial-in by phone



+1 646 828 8193 (U.S.)

+44 (0)330 165 3655 (UK)

+49 (0)69 2222 25574 (GER)


To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.


Conference ID: 5239371


Access the audio webcast


Click here:

Access Webcast

A conference call replay will be available by using the following link:



QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2022, QIAGEN employed more than 6,200 people in over 35 locations worldwide. Further information can be found at


John Gilardi

Vice President, Head of Corporate Communications and Investor Relations

+49 2103 29 11711

+49 152 018 11711

+1 240 686 2222


Phoebe Loh

Senior Director Investor Relations

+49 2103 29 11457

+49 152 018 11457


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.